Rxsight Stock

Rxsight ROE

The Return on Equity (ROE) of Rxsight (RXST) as of Aug 8, 2026 is -14.13 %. In the previous year, Return on Equity (ROE) was -9.76 % — a change of 44.70% (lower).

ROE

-14.13 %

YoY

44.70%

Last updated:

In 2026, Rxsight's return on equity (ROE) was -14.13 %, a 44.70% increase from the -9.76 % ROE in the previous year.

Access this data via the Eulerpool API

Rxsight Stock analysis

What does Rxsight do? Rxsight Inc is an innovative company that specializes in developing innovative solutions for eye treatments. The company aims to make a positive contribution to the quality of life for patients suffering from eye problems. Rxsight Inc was founded in 2008 by Jim Taylor, who had previously worked in computer graphics at Pixar Animation Studios and was now involved in new technologies for ophthalmology. The business model of Rxsight Inc is based on the development and marketing of medical products that improve the treatment of eye diseases. The company focuses on the field of dynamic ophthalmology, which aims to improve treatment options for eye diseases by focusing on the influence of eye movements and changes in pupil size. Rxsight Inc is divided into various divisions, with an important division focusing on research and development of products that can improve the treatment of eye diseases. The company invests heavily in developing innovative products. Additionally, Rxsight Inc is also involved in the manufacturing and marketing of medical products. Rxsight Inc's products include special contact lenses that can be individually customized through precise measurement of the eye lens. These contact lenses can help patients achieve better visual quality after eye surgery. Rxsight Inc also offers certain measuring devices that are used for measuring and analyzing eye movements and pupil size. Another important product from Rxsight Inc is the "Light Adjustable Lens System," which is a system for intraocular lenses that operates based on feedback from light and energy. The system allows for an individualized process for adjusting the strength of intraocular lenses. With the "Light Adjustable Lens System," patients can achieve significantly improved visual quality after cataract surgery. Overall, Rxsight Inc has established itself as an innovative company in ophthalmology. The company focuses on research and development to provide new technologies for the treatment of eye diseases. Rxsight Inc emphasizes dynamic ophthalmology to consider the influence of eye movements and pupil size in the therapy of eye diseases. With its products, Rxsight Inc makes an important contribution to improving the visual quality of patients. Rxsight is one of the most popular companies on Eulerpool.

ROE Details

Decoding Rxsight's Return on Equity (ROE)

Rxsight's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Rxsight's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Rxsight's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Rxsight’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Rxsight stock

Return on Equity (ROE) of Rxsight is -14.13 % in 2026.

Return on Equity (ROE) of Rxsight changed from -9.76 % to -14.13 %, representing a 44.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Rxsight since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Rxsight with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Rxsight

All Key Metrics — Rxsight